NCT05211986View on ClinicalTrials.gov

Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 13, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Muscle Atrophy
Interventions
DRUG

IMM01-STEM

IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.

Trial Locations (2)

92618

Orthopaedic Specialty Institute, Irvine

92868

University of California, Irvine - Alpha Stem Cell Clinic, Orange

Sponsors

Lead Sponsor

Immunis, Inc.
All Listed Sponsors
lead

Immunis, Inc.

INDUSTRY

NCT05211986 - Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. | Biotech Hunter | Biotech Hunter